The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.
September 27th 2024
Shyam A. Patel, MD, PhD, discusses findings from a meta-analysis of the effect of clonal hematopoiesis on outcomes for hematopoietic stem cell transplant.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Community Oncology Connections™: Selecting and Sequencing Therapy for Patients With DLBCL in an Era of Expanding Options
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Acalabrutinib Approved in Japan for Relapsed/Refractory CLL
January 25, 2021 - The Japanese Ministry of Health, Labour and Welfare approved the BTK inhibitor acalabrutinib for use in adult patients with relapsed/refractory chronic lymphocytic leukemia, including small lymphocytic lymphoma
Axicabtagene Ciloleucel Approved in Japan for Relapsed/Refractory LBCL
January 22, 2021 — The Japan Ministry of Health, Labour and Welfare has approved the CAR T-cell therapy axicabtagene ciloleucel for use in the treatment of adult patients with certain relapsed/refractory large B-cell lymphomas.
Adult Nonmalignant Hematology Is an Endangered Field That Merits Protection
January 21st 2021The scope of adult nonmalignant hematology can be broad and includes thrombotic and hemorrhagic disorders, transfusion medicine, hemoglobin disorders including sickle cell disease and thalassemia, anemia, thrombocytopenia, leukocytosis, leukopenia, and disorders of iron metabolism.
Capitalizing on Cellular Therapies in Lymphoma and Myeloma
January 18th 2021In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.
Could Orca-T Unlock New Path of Reduced Mortality, Prevent GVHD Posttransplant?
Steven Devine, MD, discusses the non-relapse mortality data with Orca-T and how this technologic approach is changing how providers approach patients with hematologic malignancies following transplant.